Vericel to Host Third-Quarter 2016 Earnings Webcast and Conference Call on November 7, 2016
October 31 2016 - 7:00AM
Vericel Corporation (NASDAQ:VCEL), a leading developer of
autologous expanded cellular therapies for the treatment of severe
diseases and conditions, today announced the following webcast and
conference call:
What: |
Vericel Corporation Third-Quarter 2016 Earnings
Call |
When: |
Monday, November 7, 2016 at 4:30pm (ET) |
Where: |
http://investors.vcel.com/events.cfm |
How: |
The conference call will be available live in the
Investors section of the Vericel website at
http://investors.vcel.com/events.cfm. Please access the site at
least 15 minutes prior to the scheduled start time in order to
download the required audio software if necessary. |
|
|
|
To participate in the live call by telephone,
please call (877) 312-5881 and reference Vericel Corporation
third-quarter 2016 investor conference call. If calling from
outside the U.S., please use the international phone number (253)
237-1173. |
If you are unable to participate in the live call, the webcast
will be available at
http://investors.vcel.com/events.cfm until November 7, 2017. A
replay of the call will also be available until 07:29 pm (EST) on
November 11, 2016 by calling (855) 859-2056, or from outside the
U.S. (404) 537-3406. The conference ID is 7652507.
About Vericel CorporationVericel Corporation is a leader in
developing autologous expanded cellular therapies for use in the
treatment of patients with severe diseases and conditions.
The company markets two autologous cell therapy products in the
U.S.: Carticel® (autologous cultured chondrocytes), an autologous
chondrocyte implant for the treatment of cartilage defects in the
knee, and Epicel® (cultured epidermal autografts), a permanent skin
replacement for the treatment of patients with deep-dermal or
full-thickness burns comprising greater than or equal to 30% of
total body surface area. Vericel is also developing MACI®, a
third-generation autologous chondrocyte implant for the treatment
of cartilage defects in the knee, and ixmyelocel-T, an autologous
multicellular therapy for the treatment of advanced heart failure
due to ischemic dilated cardiomyopathy. For more information,
please visit the company’s website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of
Vericel Corporation. © Vericel Corporation. All rights
reserved.
CONTACT:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2024 to May 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From May 2023 to May 2024